Company Directory

Company Directory

Company Directory - Novartis AG

Company Details - Novartis AG

Novartis AG Logo

Novartis AG

Website

Basel, Switzerland

NYSE: NVS, Swiss Exchange: NOVN 

ISIN: CH0012005267

140 Locations

Novartis AG is a global healthcare company that provides innovative healthcare solutions to meet the evolving needs of patients worldwide, focusing on both patented medicines and generic pharmaceuticals.

CCI Score

CCI Score: Novartis AG

2.88

-0.01%

Latest Event

Novartis 2024 Political Contributions and Lobbying Activity

Novartis AG's profile reveals that during the 2024 cycle, the company contributed approximately $972,834 in campaign donations and spent around $6,220,000 on lobbying activities, including allocations to dark money groups and super PACs. This data, released by the FEC and Senate records in early 2025, highlights the company's significant political influence efforts.

Take Action

So what can you do? Support Novartis by shopping, spreading the word, or offering your support.

Use Your Voice
OTHER TOOLS
Investigate
Share the Score
SUPPORT CCI

OBJECTOR

Novartis AG is currently rated as an Objector.

0 to +9 CCI Score
These companies deliberately avoid direct involvement with authoritarian practices. While they do not actively challenge oppressive regimes, they maintain a neutral stance to ensure they are not complicit in supporting such systems.

Latest Events

  • Novartis 2024 Political Contributions and Lobbying Activity Logo
    FEB
    06
    2025

    Novartis AG's profile reveals that during the 2024 cycle, the company contributed approximately $972,834 in campaign donations and spent around $6,220,000 on lobbying activities, including allocations to dark money groups and super PACs. This data, released by the FEC and Senate records in early 2025, highlights the company's significant political influence efforts.

  • -50

    Political Contributions and Lobbying Efforts

    April 30

    The disclosed political contributions and substantial lobbying expenditures, particularly involving dark money channels, raise concerns about the potential alignment with entrenched, non-transparent political interests. Such practices may contribute to undue influence over policy-making and indirectly support authoritarian tendencies, warranting a negative assessment through an anti-fascist lens.

    Novartis AG Profile: Summary • OpenSecrets

  • Novartis PAC Financial Summary Logo
    JAN
    01
    2025

    The FEC record for the Novartis Corporation Political Action Committee details relatively low political contributions and disbursements, with total receipts of $64,076.17 and total disbursements of $68,784.57. This data indicates minimal involvement in political funding, suggesting a neutral position in terms of partisan influence or support for authoritarian policies.

  • +0

    Political Contributions and Lobbying Efforts

    April 30

    The committee's financial summary reflects very modest contributions and expenditures, which implies that Novartis is not actively engaging in political funding that would support far‐right or authoritarian agendas. This neutral level of activity is notable given the current political climate.

    Novartis Corporation Political Action Committee - FEC

  • Novartis Plans to Lay Off 680 Employees Logo
    APR
    09
    2024

    Novartis announced plans on April 9, 2024 to lay off 680 staff members across its development organization in Switzerland and the United States over the next two to three years. The move is part of a restructuring effort that follows previous layoffs, causing concerns over worker job security and labor rights.

  • -50

    Labor Relations and Human Rights Practices

    April 30

    The planned layoffs of 680 employees reflects a negative impact on labor relations and human rights practices. This decision undermines job security and worker protections, which is particularly concerning from an anti-fascist perspective that values strong labor rights and the protection of marginalized workers.

    Novartis plans to axe 680 employees

  • Novartis Enhances Labor and Supply Chain Human Rights Protections Logo
    JAN
    01
    2024

    Novartis has updated its approach to managing labor rights risks in its supply chain by implementing an enhanced External Partner Risk Management framework, launching its Labor Rights 2.0 program in 2024, and introducing a digital workers voice platform. These initiatives aim to safeguard vulnerable workers and ensure compliance with human rights standards among external partners.

  • +80

    Labor Relations and Human Rights Practices

    April 30

    Novartis’s launch of Labor Rights 2.0 and its digital 'workers voice' platform represents a strong commitment to protecting labor rights. The efforts to conduct risk assessments, audits, and corrective actions, especially regarding allegations of forced labor, improve protections for vulnerable workers in the supply chain, marking a positive step against exploitative practices.

    Human rights - Novartis

  • +75

    Supply Chain Ethics

    April 30

    The detailed External Partner Risk Management (EPRM) framework and targeted assessments for high-risk external suppliers in the supply chain indicate a proactive approach to addressing human rights risks, including risks of forced labor in raw material sourcing.

    Human rights - Novartis

  • Novartis AG Lobbying Expenditure in 2023 Logo
    DEC
    31
    2023

    Novartis AG spent $5,930,000 on federal lobbying activities during 2023, as reported by OpenSecrets using Senate Office of Public Records data. The expenditure reflects the company's effort to influence public policy and regulatory decisions.

  • -40

    Political Contributions and Lobbying Efforts

    April 30

    The reported nearly $6M lobbying expenditure indicates a significant investment in political influence. From an anti-fascist perspective, such heavy spending on lobbying may help entrench corporate interests over democratic accountability and can potentially support policies favoring authoritarian or undemocratic approaches.

    Novartis AG Lobbying Profile

  • Novartis Complies with Child Labor Due Diligence in Supply Chain Logo
    DEC
    31
    2023

    Novartis released its detailed report on child labor due diligence for the period January 1, 2023, to December 31, 2023, demonstrating compliance with Swiss regulations and a robust system for monitoring, auditing, and remediating child labor risks within its supply chain.

  • +70

    Labor Relations and Human Rights Practices

    April 30

    Novartis has implemented comprehensive due diligence procedures to ensure compliance with international labor standards regarding child labor. The report details rigorous audits, clear remediation measures, and strict enforcement of ethical policies, reflecting a strong commitment to protecting human rights in its operations and supply chain.

    PDF Novartis report on child labor due diligence in our supply chain

  • +65

    Supply Chain Ethics

    April 30

    The report highlights a rigorous approach to supply chain risk management by screening thousands of third parties and enforcing corrective actions via audits and remediation plans. These practices underscore Novartis's commitment to ethical supply chain management and reducing human rights risks, including those related to child labor.

    PDF Novartis report on child labor due diligence in our supply chain

  • Novartis Transparent Lobbying Disclosure and Responsible Public Engagement Logo
    NOV
    01
    2023

    Novartis has detailed its lobbying expenditures in compliance with US federal law and EU regulations, emphasizing a commitment to transparency and responsible engagement in public policy. The company outlines its approach to evidence-based dialogue with policymakers, aiming to support innovation and positive impacts on healthcare policy.

  • +40

    Political Contributions and Lobbying Efforts

    April 30

    Novartis demonstrates responsible political behavior by transparently disclosing all lobbying expenditures and engaging in evidence-based policy dialogue. This adherence to legal requirements and ethical standards contributes positively to democratic processes and accountability, countering tendencies toward opaque corporate political influence.

    Public Policy

  • Novartis Engages in Transparent Public Policy Advocacy Logo
    NOV
    01
    2023

    Novartis outlined its public policy approach, emphasizing transparent and ethical lobbying practices. The company details adherence to federal contribution limits for its PAC, a commitment to evidence‐based dialogue with policymakers, and a focus on creating progressive legislative foundations to support innovation in healthcare.

  • +40

    Political Contributions and Lobbying Efforts

    April 30

    The article notes that Novartis follows strict federal contribution limits and clear guidelines in managing its PAC. This transparent approach to political contributions and ethical lobbying practices promotes accountability in public affairs, aligning with democratic, anti-authoritarian principles.

    Public Policy

  • +50

    Executive Political Engagement

    April 30

    Novartis demonstrates responsible executive political engagement by actively participating in policy discussions, emphasizing evidence-based data and transparent practices. Its commitment to constructive dialogue with regulatory bodies and governments positively contributes to a progressive legislative environment.

    Public Policy

  • Novartis Settlement for Improper Payments and Kickbacks Logo
    JUL
    01
    2020

    Novartis Pharmaceuticals Corporation agreed to pay over $642 million to settle allegations of fraudulent use of copay assistance foundations and kickbacks to doctors, practices that involved manipulating Medicare patient copay processes and scheduling speaker programs as a means to drive prescriptions.

  • -80

    Business Practices and Ethical Responsibility

    April 30

    The settlement details reveal that Novartis engaged in unethical business practices by channeling payments through foundations to cover patient copays and by providing kickbacks to physicians. These actions not only manipulated Medicare mechanisms and contributed to increased healthcare costs, but also undermined public trust in the healthcare system. Such behavior is indicative of a broader disregard for ethical business practices, warranting a strongly negative score in the Business Practices and Ethical Responsibility category.

    Novartis Pays Over $642 Million to Settle Allegations of Improper Payments to Patients and Physicians

  • Novartis Corporate Responsibility Guideline Update Logo
    JUN
    01
    2017

    Novartis released an updated Corporate Responsibility Guideline outlining its internal governance framework and commitment to ethical business practices including transparent oversight, access to medicine initiatives, and integration of corporate responsibility metrics into executive performance. The document, approved in its latest update in June 2017, details the roles of the Corporate Responsibility Board, Governance Committees, and cross-divisional coordination aimed at improving global health and ensuring responsible operations.

  • +50

    Business Practices and Ethical Responsibility

    April 30

    The guideline demonstrates Novartis' positive commitment to ethical business practices by instituting robust corporate responsibility governance, transparency in reporting, and clear accountability measures. These actions support progressive values and help mitigate risks associated with corporate complicity in authoritarian or exploitative practices.

    PDF Corporate Responsibility Guideline - Novartis

  • Union Protest Over Novartis Job Cuts Logo
    OCT
    29
    2011

    Unions in Basel protested Novartis' announcement of cutting 2,000 jobs, arguing that the company's decision to prioritize profits over job security undermines worker rights. The cuts include 1,100 domestic positions and 900 in the United States, while 700 new roles are planned in low-cost countries.

  • -60

    Labor Relations and Human Rights Practices

    April 30

    Novartis' decision to cut a significant number of jobs, impacting domestic employment and sparking union protests, reflects a disregard for worker welfare. This move prioritizes profit over the rights and security of workers, aligning with practices that undermine labor relations and human rights.

    Protestors urge Novartis to scrap job cuts

Corporate Financials

Revenue
2025
$51.20B
Total Assets
2025
$113.50B
Operating Income
2025
$12.03B
Total Equity
2025
$67.80B

Employees: 109,000

Industries

325411
Medicinal and Botanical Manufacturing
325412
Pharmaceutical Preparation Manufacturing
541711
Research and Development in Biotechnology